TIPE3, a Lipid Second-Messenger Protein, Multifunctionally Regulates Pan-Cancer Progression and Therapeutic Resistance

Current cancer therapeutics often face limitations due to poor therapeutic index, off-target effects, and the complex, heterogeneous nature of tumors. Understanding novel regulatory proteins that influence multiple oncogenic pathways is crucial for developing more effective and targeted therapies. The TNFAIP8 family of lipid transfer proteins, particularly TIPE3, has emerged as a critical player, connecting phosphoinositide signaling to diverse aspects of cancer biology. This connection offers a potential new avenue for therapeutic intervention by targeting a protein involved in fundamental cellular processes.

This comprehensive review systematically synthesized current evidence on TIPE3 (encoded by TNFAIP8L3), a member of the TNFAIP8 family, focusing on its roles in cancer progression, therapeutic resistance, and clinical outcomes. Researchers analyzed findings from numerous studies across various malignancies, including lung, breast, pancreatic, gastric, colorectal, ovarian, cervical cancers, glioblastoma, and acute myeloid leukemia. The review critically examined TIPE3's functional duality, its regulation by localization and epigenetics, and its potential for therapeutic stratification, while also addressing conflicting data, particularly in colorectal cancer.

TIPE3 functions as a lipid second-messenger transfer protein, directly facilitating the transfer of PIP2 and PIP3, thereby modulating several critical oncogenic pathways. The review highlights that TIPE3 generally promotes tumor growth, invasion, immune remodeling, autophagy, and platinum resistance across a broad spectrum of cancers. It exerts its influence by modulating key signaling cascades such as PI3K/AKT, MEK/ERK, Wnt/β-catenin, NF-κB, Hedgehog, and mitochondrial stress pathways. This broad impact underscores its central role in tumorigenesis.

TIPE3 exhibits a pan-cancer functional duality, generally facilitating tumor progression and therapeutic resistance in most malignancies, while demonstrating tumor-suppressive effects in specific contexts like head and neck squamous cell carcinoma.

Conflicting findings, particularly in colorectal cancer, were attributed to disparities in mRNA versus protein assessment, tumor composition, immune contexture, subcellular localization, and treatment exposure. The review underscores TIPE3's potential as a valuable biomarker and therapeutic target, despite the absence of TIPE3-targeted therapies in clinical application.